Mylan has been in the news for hiking prices on its EpiPen. The stock is flat since we recommended it in March, but we now ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

The stock is down 17.3% since reporting ... Is now the time to buy ANI Pharmaceuticals? Access our full analysis of the ...

Tarsus Pharmaceuticals (TARS) announced the commencement of an underwritten public offering of $100M of shares of its common stock. All shares in the proposed offering are to be sold by Tarsus.

Viatris Inc., formed in 2020 through the merger of Mylan and Upjohn (a former ... as a significant player in the pharmaceutical industry. The company’s stock has shown mixed performance, with ...

These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future ...

Ionis Pharmaceuticals IONS underwent analysis by ... Typically, analysts will rate each stock once a quarter. Some analysts will also offer forecasts for metrics like growth estimates, earnings ...

BMO Capital initiated coverage of Rocket Pharmaceuticals (RCKT ... Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and negative factors.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed ...

Keeping that in mind, here is one healthcare stock poised to generate sustainable market-beating returns and two we’re swiping left on. Formed in 2020 through the merger of Mylan and Upjohn ...

However, the stock was also likely negatively impacted by CNBC Mad Money host Jim Cramer's comments on Friday. He expressed reservations about buying shares of Recursion Pharmaceuticals in light ...

In February, Arrowhead Pharmaceuticals closed a global licensing and collaboration agreement with Sarepta Therapeutics Inc. Arrowhead receives a $500 million upfront payment and $325 million through ...